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ABSTRACT
Background  Oral mucositis  (OM)  is a  side effect of 
chemotherapy in head and neck cancer. Severe OM 
often has a  large  impact on quality of  life. Therefore, 
the  treatment of OM during chemotherapy  is very 
important. It was recently reported that Hangeshashinto 





















TJ-14  significantly  reduced  the duration of ≥ grade 2 
OM.






head and neck cancer; oral mucositis
Chemotherapy  is an essential  treatment  for head and 
neck cancer,  and  the docetaxel-cisplatin-5-fluorouracil 
(TPF)  regimen  is common.1, 2 Oral mucositis (OM) is 











It was  recently  reported  that Hangeshashinto 
(TJ-14),  a  Japanese  traditional medicine  (Kampo), was 
effective  for OM caused by  fluorinated pyrimidine-
based agents,  including 5-fluorouracil,  that are used 
in colon cancer therapies.7, 8 While  several  treatments 
for OM are  temporarily  effective  as  symptomatic 
therapy, none have been proven  to maintain  long-term 
efficacy. The aims of  this  study were  to assess  the ef-
ficacy of TJ-14  for  the prevention and/or  treatment of 
chemotherapy-induced OM in a  randomized, double-
blind, placebo-controlled exploratory clinical  trial  in 
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Study protocol
Both TJ-14 and placebo were administered at a dose of 
2.5 g after each meal  (three  times per day),  for a  total 
daily dose of 7.5 g. Lactose was used as placebo.
Lactose  is  safe  for  the patients because  there  is 
no  report  that  lactose has any  influence on  the oral 
mucositis. Both drugs were wrapped in white paper so 
they could not be  seen.  In  this double-blind, placebo-
controlled, randomized study, patients were divided into 
two groups using the Japanese Industrial Standards ran-

























Statistical  analyses were  performed  using  SAS 
University Edition  for Windows,  release 9.3  (SAS 
Institute, Cary, NC). The  incidences of both OM and 











Sixteen patients were  included  in  this  study;  there 





including  the primary  tumor  location and clinical 
stage, are shown for both groups in Table 1. No patients 
developed distant metastasis. TPF was completed in all 
patients. In the TJ-14 group, one patient had  to  reduce 
the dose  to 75% and another  required a  reduction  to 
80%, in both cases due to old age.
The overall incidence of OM was 75% (six patients) 








in the TJ-14 group and 3.7 days  in  the placebo group. 
TJ-14  significantly  reduced  the duration of ≥ grade 2 









and neck cancer.7, 9 Reducing  the  incidence of adverse 
events related to chemotherapy facilitates the treatment. 
Many regimens,  including TPF, cause widespread OM 
throughout  the oral cavity,  and pain due  to OM can 
make oral  intake difficult, which may  reduce physical 
strength and immunity. In some cases, this can prevent 





motherapy in head and neck cancer.9, 10 There are some 
reports that grade 3/4 OM occurred in more than 30% 
patients who underwent TPF. However, no  reports 
have shown that TJ-14  is  effective  for OM induced by 
chemotherapy alone in head and neck cancer. Our study 
examined the effects of OM in this setting, and demon-
strated statistical  significance  in  terms of  reducing  the 
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duration of severe, ≥ grade 2 OM compared to placebo.
Pain relief for OM is often achieved using NSAIDs, 





which have been shown  to  induce side effects  such as 
pseudoaldosteronism and herbal medicine-induced 




patients gargled  the medication, which  is a  safer and 
more effective method of administration  for head and 
neck cancer patients.
Table 1. Patients characteristic
Case no. Subsite TNM Age (yr) Gender
1 T Oropharynx T4aN0M0 53 M
2 T Oropharynx T4aN2cM0 62 M
3 T Hypopharynx T3N2bM0 83 M
4 T Hypopharynx T4aN2cM0 62 F
5 T Oropharynx T4aN1M0 62 M
6 T Oropharynx T4aN2cM0 54 M
7 T Hypopharynx T4aN2cM0 63 M
8 T Oropharynx T3N2cM0 73 M
9 P Hypopharynx T4aN2cM0 58 M
10 P Oropharynx T4aN2cM0 64 M
11 P Larynx T2N0M0 72 M
12 P Hypopharynx T4aN2cM0 52 M
13 P Hypopharynx T2N2cM0 49 M
14 P Maxillary sinus T3N0M0 65 F
15 P Maxillary sinus T4aN0M0 79 M
16 P Oropharynx T3N3M0 67 M
TNM staging system is defined by Union for  International Cancer Control classification system. F,  female; M, male; P, placebo;  
T, TJ-14; yr, years.
Table 2. Comparison between TJ-14 and placebo for OM
TJ-14 Placebo P value







On set (day) 9.7 6.7 0.258
Duration of OM (day) 4.7 6.7 0.522
Duration of OM ≥ G2 (day) 1.7 3.7 0.039
G2, grade 2; G3, grade 3; G4, grade 4.
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TJ-14  is  composed of  seven herbal compounds: 
Pinelliae  Tuber,  Scutellariae Radix,  Zingiberis 
Rhizoma, Ginseng Radix, Glycyrrhizae Radix, 
Zizyphi Fructus, and Coptidis Rhizoma. Several herbal 
substances have known mechanisms  that  reduce  the 














effects  in both  in vivo and  in vitro  studies.22, 23 We 
speculate  that  the effects of TJ-14 in head and neck 
cancer are similar to those in other cancers. We confirm 
in this study that TJ-14  is effective for OM induced by 
TPF in patients with head and neck cancer and shorten 
the duration of ≥ grade 2 OM.
When patients experience  relief  from OM-related 




This  study has  several  limitations. First,  since 
this  study size was  small,  the difference between  the 
treatment and placebo groups may not in fact have been 
significant. Second, the distribution of primary disease 





and neck cancer. Further  studies are  required  to  fully 
understand the biological activity of TJ-14 against OM 
in this population.
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